Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of therapies for metabolic and endocrine disorders. Company press releases highlight progress across a pipeline that includes VK2735 for obesity and related metabolic conditions, VK2809 for lipid and liver disorders such as NASH and NAFLD, VK0214 for X-linked adrenoleukodystrophy (X-ALD), and an emerging program of dual amylin and calcitonin receptor agonists (DACRAs) for obesity and other metabolic diseases.
For VK2735, Viking regularly issues news on clinical milestones in both subcutaneous and oral tablet formulations. Recent announcements describe positive Phase 2 VENTURE trial results in obesity, with statistically significant weight loss and encouraging safety and tolerability, as well as Phase 2 VENTURE-Oral Dosing data showing meaningful weight reduction after 13 weeks of once-daily oral therapy. Additional releases cover the initiation and progress of the Phase 3 VANQUISH-1 and VANQUISH-2 trials, which evaluate weekly subcutaneous VK2735 in adults with obesity or overweight, including those with type 2 diabetes, over 78 weeks.
News items also detail exploratory maintenance dosing studies of VK2735 that examine monthly subcutaneous, weekly oral, and daily oral regimens following initial weight loss. Beyond obesity, Viking’s updates discuss VK2809’s Phase 2b success in biopsy-confirmed NASH and fibrosis, as well as Phase 2a results in NAFLD with elevated LDL-C, and VK0214’s Phase 1b data in X-ALD showing reductions in very long-chain fatty acids. Investors following VKTX news can expect coverage of clinical data presentations at scientific meetings, participation in healthcare and investor conferences, and SEC-reported corporate updates on financial results and pipeline status.
Viking Therapeutics (VKTX) announced its Q3 2022 financial results, reporting a net loss of $15.8 million, or $0.21 per share, compared to $13.2 million, or $0.17 per share, in Q3 2021. The company ended the quarter with $155 million in cash, supporting ongoing clinical trials for VK2809, VK2735, and VK0214, with data expected in 2023. The Phase 2b VOYAGE study for VK2809 is on track for Q4 2022 enrollment completion. Increased R&D and G&A expenses were noted, affecting the overall financial performance.
Viking Therapeutics (NASDAQ: VKTX) announced the release of its third-quarter 2022 financial results on October 26, 2022, after market close. A conference call will be held on the same day at 4:30 p.m. Eastern Time to discuss these results and provide corporate updates. The company's pipeline includes VK2809, in Phase 2b for NASH, and VK2735, in Phase 1 for metabolic disorders, showcasing ongoing innovation in therapies targeting metabolic and endocrine conditions.
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its participation in two investor conferences from September 12-14, 2022. At the H.C. Wainwright 24th Annual Global Investment Conference, Dr. Lian will deliver a presentation on September 14 at 12:30 PM Eastern, with a hybrid format available. Additionally, Viking management will engage in 1-on-1 meetings at the Morgan Stanley 20th Annual Global Healthcare Conference during the same dates, held at the Sheraton New York Hotel. Webcasts of the presentations will be accessible via the Viking Therapeutics website.
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will participate in a fireside chat at the BTIG Biotechnology Conference 2022 on August 8-9, 2022. The event will be a hybrid format, facilitating both in-person and virtual attendance. Viking focuses on developing innovative therapies for metabolic and endocrine disorders, including its clinical programs VK2809, VK2735, and VK0214. VK2809 is currently in a Phase 2b study for non-alcoholic steatohepatitis, showing promising results for lipid and metabolic disorders.
Viking Therapeutics (NASDAQ: VKTX) reported Q2 2022 financial results, showing a net loss of $17.4 million, or $0.23 per share, compared to a loss of $15.4 million in Q2 2021. With $169 million in cash, the company is positioned to advance its clinical programs. Key updates include the VOYAGE Phase 2b study for VK2809, expected to complete enrollment in Q4 2022, and initial results from the Phase 1 study of VK2735 anticipated by year-end. Following FDA clearance, dosing for VK0214 in X-ALD patients is set to resume, with enrollment completion expected in H1 2023.
Viking Therapeutics (NASDAQ: VKTX) announced it will release its second quarter 2022 financial results on July 27, 2022, after market close. A conference call discussing these results and corporate updates is scheduled for 4:30 p.m. Eastern Time on the same day. Interested parties can join the call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 internationally. For more details on the company's clinical programs, including VK2809 and VK2735, which target metabolic and endocrine disorders, visit www.vikingtherapeutics.com.
Viking Therapeutics (VKTX) announced the FDA has lifted the clinical hold on its Phase 1b trial for VK0214, aimed at treating X-linked adrenoleukodystrophy (X-ALD). The hold was lifted after an in vivo genotoxicity study showed no adverse effects. Enrollment for the trial will resume shortly. VK0214, a thyroid hormone beta receptor agonist, has achieved orphan drug designation and previously demonstrated encouraging safety and efficacy in earlier trials. The Phase 1b study targets patients with the AMN form of X-ALD, with primary objectives focused on safety and tolerability.
Viking Therapeutics, Inc. (NASDAQ: VKTX) will have CEO Brian Lian, Ph.D., participate in a fireside chat at the William Blair Biotech Focus Conference 2022 on July 12-13, 2022. The event will be held at The St. Regis, New York, with a webcast available starting July 11, 2022. Viking is focused on developing novel therapies for metabolic and endocrine disorders, with ongoing clinical programs including VK2809 for NASH and VK0214 for X-ALD. For more details, visit www.vikingtherapeutics.com.
Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will present at the H.C. Wainwright Global Investment Conference from May 23-25, 2022. The presentation will be available online on May 24 at 7:00 a.m. Eastern. This hybrid conference includes both in-person and virtual participation. Viking's clinical programs focus on metabolic and endocrine disorders, with ongoing studies for VK2809, VK0214, and VK2735. VK2809 is currently in a Phase 2b trial for NASH and fibrosis, following successful Phase 2a results for NAFLD.
Viking Therapeutics (VKTX) reported its Q1 2022 financial results, showing a net loss of $16.1 million ($0.21 per share), up from $14 million ($0.19 per share) year-over-year. The company highlighted the ongoing Phase 2b VOYAGE study for VK2809 in NASH, with enrollment completion expected in 2H22. Additionally, the Phase 1 trial of VK2735 is ongoing, with results anticipated by year-end. With a cash balance of $185 million, Viking maintains a strong financial position to support its clinical programs through key upcoming data readouts.